VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation

AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19

AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development

AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU

AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test